Pharmacological Approaches to Combating Antimicrobial Resistance (R01)
The summary for the Pharmacological Approaches to Combating Antimicrobial Resistance (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Pharmacological Approaches to Combating Antimicrobial Resistance (R01): -Purpose. The National Institute of Allergy and Infectious Diseases (NIAID) invites Research Project Grant (R01) applications from institutions/organizations that propose to apply pharmacokinetic and pharmacodynamic principles to studies on the prevention of emergence of antimicrobial drug resistance. This initiative is also intended to stimulate and strengthen collaborations between antimicrobial pharmacologists and infectious disease researchers to provide a synergistic, integrated approach that will form the basis for future clinical management of antimicrobial drug resistance. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. NIAID anticipates awarding a total of $3 million in FY 2008 to fund 5-8 awards for up to 4 years. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
|Federal Grant Title:||Pharmacological Approaches to Combating Antimicrobial Resistance (R01)|
|Federal Agency Name:||National Institutes of Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-AI-07-025|
|Type of Funding:||Grant|
|CFDA Descriptions:||Microbiology and Infectious Diseases Research|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Oct 19, 2007|
|Posted Date:||Apr 06, 2007|
|Creation Date:||Apr 06, 2007|
|Archive Date:||Nov 18, 2007|
|Total Program Funding:||$3,000,000|
|Maximum Federal Grant Award:||$500,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- Independent school districts For profit organizations other than small businesses Private institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Public and State controlled institutions of higher education Small businesses Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) City or township governments
- Additional Information on Eligibility
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Similar Government Grants
- • Biomedical Prevention of HIV Research Education (R25)
- • Partnerships for Next Generation Biodefense Diagnostics (R01)
- • National Biocontainment Laboratories (NBLs) Operations Support Limited Competition (UC7)
- • Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pat...
- • Non-Antibiotic Selectable Markers for Biodefense (R21)
- • Partnerships to Improve Diagnosis and Treatment of Selected Drug-Resistant Healthcare-Asso...
- • Cooperative Research Partnerships for Biodefense (U01)
- More Grants from the National Institutes of Health
- • Zika Virus (ZIKV) Complications (R21)
- • Sex Hormone Induced Thromboembolism in Pre-Menopausal Women (R61/R33)
- • Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the...
- • Basic Mechanisms of Brain Development Mediating Substance Use and Dependence (R01)
- • Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidi...